The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
MeSH Review

Preferred Provider Organizations

 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

High impact information on Preferred Provider Organizations

  • METHODS: The sample consisted of 218 continuous enrollees in preferred provider organization and/or indemnity plans who had any MDD admissions during fiscal years 1992 to 1995 [1].
  • RESULTS: No significant differences in any of the five indicators of primary care quality were found between patients with independent provider association/preferred provider organization (IPA/PPO) and fee-for-service insurance [2].
  • This article is an analysis of patient choice of providers by the employees of the Security Pacific Bank of California and their dependents who have access to the Med Network Preferred Provider Organization (PPO) [3].
  • This paper addresses how UR has evolved, how UR is used today by different delivery mechanisms (i.e., Medicare, health maintenance organizations, preferred provider organizations, Blue Cross, and commercial insurers), the cost effects of various UR approaches, and how UR will be used in the future [4].
  • STUDY DESIGN: Descriptive retrospective analysis of medical and prescription claims data from a large preferred provider organization in the Midwest. METHODS: During an index period of January through May 31, 2000, patients new to COX-2 therapy were evaluated 365 days before and after their first prescription [5].
 

Associations of Preferred Provider Organizations with chemical compounds

 

Gene context of Preferred Provider Organizations

References

  1. Effects of a behavioral health carve-out on inpatient-related quality indicators for major depression treatment. Merrick, E.L. Medical care. (1999) [Pubmed]
  2. The impact of insurance type and forced discontinuity on the delivery of primary care. Flocke, S.A., Stange, K.C., Zyzanski, S.J. The Journal of family practice. (1997) [Pubmed]
  3. Patient choice of providers in a preferred provider organization. Wouters, A.V., Hester, J. Medical care. (1988) [Pubmed]
  4. Hospital utilization review: past experience, future directions. Ermann, D. Journal of health politics, policy and law. (1988) [Pubmed]
  5. Prescribing COX-2s for patients new to cyclo-oxygenase inhibition therapy. Cox, E.R., Motheral, B., Frisse, M., Behm, A., Mager, D. The American journal of managed care. (2003) [Pubmed]
  6. Preferred provider organizations, price-fixing and Section 1 of the Sherman Act. Bluhm, R.J. Health matrix. (1987) [Pubmed]
  7. HMO and PPO growth and hospital utilization and payment: a recursive model. Hu, T.W., Sullivan, S.D., Scheffler, R.M. Advances in health economics and health services research. (1992) [Pubmed]
  8. Preferred provider organizations: a fiscal perspective. Part 5. Schmitt, J.P. Healthcare financial management : journal of the Healthcare Financial Management Association. (1983) [Pubmed]
  9. Documentation of referrals: recording bias due to patient insurance type. Lawler, F.H., Bisonni, R.S., Spann, S.J. The Family practice research journal. (1990) [Pubmed]
 
WikiGenes - Universities